Marshall Wace
NAMS icon

Marshall Wace’s NewAmsterdam Pharma NAMS Stock Holding History

Marshall Wace’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-264,802
Closed -$8.48M – 3536
2026
Q1 		$8.48M Buy
+264,802
New +$8.63M 0.01% 1054
2025
Q1 		– Sell
-288,446
Closed -$7.41M – 2930
2024
Q4 		$7.41M Buy
288,446
+178,322
+162% +$3.79M 0.01% 905
2024
Q3 		$1.83M Buy
110,124
+88,293
+404% +$1.53M ﹤0.01% 1405
2024
Q2 		$419K Sell
21,831
-93,549
-81% -$1.88M ﹤0.01% 2027
2024
Q1 		$2.73M Buy
115,380
+81,439
+240% +$1.65M ﹤0.01% 1230
2023
Q4 		$379K Buy
33,941
+23,777
+234% +$218K ﹤0.01% 1811
2023
Q3 		$94K Sell
10,164
-15,197
-60% -$165K ﹤0.01% 2049
2023
Q2 		$302K Buy
+25,361
New +$336K ﹤0.01% 2139

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Marshall Wace's NAMS Position: Q2 2026 in Review

Marshall Wace sold out of NewAmsterdam Pharma (NAMS) in Q2 2026, closing a stake of 264,802 shares — an estimated $8.48M sold.

Marshall Wace first reported a position in NAMS in Q2 2023 and held it in 8 quarters. The position peaked at $8.48M in Q1 2026. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • Marshall Wace reported no remaining NewAmsterdam Pharma position as of Q2 2026 after selling out during the quarter.
  • Marshall Wace sold 264,802 NewAmsterdam Pharma shares in Q2 2026, an estimated $8.48M.
  • Marshall Wace first reported a position in NewAmsterdam Pharma in Q2 2023 and held it in 8 quarters.
  • Marshall Wace's NewAmsterdam Pharma position peaked at $8.48M in Q1 2026.
  • 194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.